A team of researchers at VCU Massey Comprehensive Cancer Center has identified a new pathway through which mutations in the ...
The gene p53 acts as a tumor suppressor and often is called the ‘guardian of the genome.’ This gene is central to maintaining genomic stability, which prevents mutations from accumulating and leading ...
The study of mutant p53 isoforms lies at the forefront of cancer biology, revealing the profound impact of TP53 gene alterations on tumor progression and ...
Memorial Sloan Kettering Cancer Center investigators and collaborators have tested rezatapopt, an oral p53 reactivator designed for tumors with TP53 Y220C, and observed antitumor activity across ...
A research team at the University of Konstanz, led by toxicologist Ivano Amelio, has demonstrated how differently individual mutations of the tumor suppressor p53 affect pancreatic carcinomas. When ...
In a recent perspective published in the journal Cell Death and Differentiation, researchers in France, Germany, and Sweden discussed the unique mutational spectrum of the transformation-related ...
TP53 mutations are crucial in cancer development and treatment response, influenced by genetic and environmental factors. In CLL and AML, TP53 serves as a significant prognostic marker, affecting ...
Approximately 25-30% of lung cancer patients lack mutations targeted by current therapies, necessitating novel approaches. New targets, including MTAP deletions, SMARC4, and p53 mutations, show ...
The reason why targeted treatment for non-small cell lung cancer fails to work for some patients, particularly those who have never smoked, has been discovered. The reason why targeted treatment for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results